Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients

AIDS

Volumn 19, Issue SUPPL. 3, 2005, Pages

  Kresina, Thomas F ^a   Eldred, Lois ^b   Bruce, R Douglas ^c   Francis, Henry ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b HEALTH RESOURCES AND SERVICES ADMINISTRATION   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; HIV primary care; HIV HCV co infection; Substance abuse treatment

Indexed keywords

BUPRENORPHINE; OPIATE AGONIST;

BEHAVIOR MODIFICATION; COMORBIDITY; DRUG DEPENDENCE TREATMENT; GENERAL PRACTITIONER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LAW; LICENCE; OPIATE ADDICTION; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE; VIRUS TRANSMISSION;

EID: 27944436971     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000192093.46506.e5     Document Type: Review

References (37)

1. Centers for Disease Control and Prevention. Table 1: Estimated numbers of diagnoses of HIV/AIDS, by year of diagnosis and selected characteristics of persons, 1999-2002 - 30 areas with confidential name-based HIV infection reporting. Available at: http://www.cdc.gov/hiv/stats/hasr1402/table1.htm. Atlanta, GA, Centers for Disease Control and Prevention. Accessed: 10 June 2004.
2. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjon O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280:544-546.
3. Stradthdee SA, Palepu A, Comelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280:547-549.
4. Gebo K, Fleishman J, Conviser R, Reilly ED, Korthuis PT, Moore RD, et al. Racial and gender disparities in receipt of HAART persist in a multi-state sample of HIV patients in 2001. JAIDS 2005; 38:96-103.
5. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15:1115-1123.
6. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27:251-259.
7. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of the drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-774.
8. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366.
9. Wang C, Vlahov, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR. Mortality in HIV-seropositive versus seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190:1046-1054.
10. Sherer R, Stieglitz K, Narra J, Jasek J, Green L, Moore B, et al. HIV multidisciplinary team work: support services improve access to and retention in HIV primary care. AIDS Care 2002; 14 (Suppl. 1):S45-S47.
11. Altice FL, Mezger J, Hodges J, Bruce RD, Marinovich A, Walton M, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis 2004; 38(Suppl. 5):S376-S387.
12. Lucas GM, Weidle PJ, Hader S, Moore RD. Directly observed antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis 2004; 38 (Suppl. 5):S409-S413.
13. Strathdee SA, Laktka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F, et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40 (Suppl. 5):S304-S312.
14. Taylor LE. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005; 40 (Suppl. 5):S355-S361.
15. Sullivan LE, Fiellin DA. Hepatitis C and HIV infections: implications for clinical care in injection drug users. Am J Addict 2004; 13:1-20.
16. Seeff LC, Hoofnagle JH. The National Institutes of Health Consensus Development Conference: Management of Hepatitis C 2002 [Appendix]. Clin Liver Dis 2003; 7:261-287.
17. Strader DB, Wright T, Thomas DL, Seeff LB, and the American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
18. Sylvestre DS, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, et al. Co-occurring hepatitis C, substance use and psychiatric illness: Treatment issues and developing integrated models of care. J Urban Health 2004; 81:719-734.
19. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Burprenorphine/naloxone collaborative study group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine/naloxone. N Engl J Med 2003; 349:949-958.
20. Ling W, Smith D. Buprenorphine: blending practice and research. J Subst Abuse Treat 2002; 23:87-92.
21. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharm Ther 1994; 55:569-580.
22. Schuh KJ, Walsh SL, Bigelow GE, Preston KL, Stitzer ML. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharm Exp Ther 1996; 278:836-846.
23. Petry NM, Bickel WK, Piasecki D, Marsch LA, Badger GJ. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000; 9:265-269.
24. Conway KP, Kane RJ, Ball SA, Poling JC, Rounsaville BJ. Personality, substance of choice, and polysubstance involvement among substance dependent patients. Drug Alcohol Depend 2003; 71:65-75.
25. Ciccocioppo R, Lin D, Martin-Fardon R, Weiss F. Reinstatement of ethanol-seeking behavior by drug cues followed by a single versus multiple ethanol intoxication in the rat: effects of natrexone. Psychopharmcology (Berl) 2003; 168:208-215.
26. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexate is associated with attenuation of ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 1998; 18:10663-10671.
27. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Marti not-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27:1717-1722.
28. Fiellin DA. Substance use disorders in HIV-infected patients: impact and new treatment strategies. Top HIV Med 2004; 12:77-82.
29. Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 2003; 12 (Suppl. 1):S3-S11.
30. Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine addiction. CNS Drugs 2005; 19:13-25.
31. Montoya ID, Gorelick DA, Preston KI, Schroeder JR, Umbricht A, Cheskin LJ, et al. Randomized trial of buprenorphine for the treatment of concurrent opiate and cocaine dependence4. Clin Pharmacol Ther 2004; 75:34-48.
32. Fudala PJ, Bridge TP, Herbert S, Wiliford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349:949-958.
33. Mattick RP, Kimber J, Breen C, Davoli M. Buprenophine maintenance versus placebo or methadone maintenance for opioid dependence (Cochrane Review). Oxford: update software. In: The Cochrane Library. Issue 3; 2003.
34. Petry NM, Bickel WK, Piasecki D, Marsch LA, Badger GJ. Elevated liver enzymes levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000; 9:265-269.
35. McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effects of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 2001; 10:296-307.
36. Hall CS, Charlesbois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus Infection in San Francisco's HIV-infected urban poor. J Gen Internal Med 2004; 19:357-365.
37. Hall CS, Charlesbois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004; 19:357-365.